COMMUNIQUÉS West-GlobeNewswire

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

03/09/2024 - 22:05

TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]

The Iowa Clinic Signs Multi-Year Agreement with Counterpart Health to Deploy Proven AI Technology to Hundreds of Providers Across the Midwest

03/09/2024 - 22:05

FRANKLIN, Tenn., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Today, Counterpart Health, Inc . (“Counterpart”), a leading AI-powered physician enablement platform, announced a multi-year agreement with The Iowa Clinic, P.C ., one [...]

Elutia to Participate in Upcoming Investor Conferences

03/09/2024 - 22:05

SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, [...]

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

03/09/2024 - 22:05

Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage [...]

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

03/09/2024 - 22:05

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company [...]

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

03/09/2024 - 22:05

GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that Company management [...]

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/09/2024 - 22:05

BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 30, 2024, [...]

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 - 22:05

BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive [...]

Rani Therapeutics to Participate in September Investor Conferences

03/09/2024 - 22:05

SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

03/09/2024 - 22:05

LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated [...]

Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

03/09/2024 - 22:05

Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to [...]

Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

03/09/2024 - 22:05

Twelve-month durability data from Metagenomi’s ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight [...]

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 - 22:05

SAN FRANCISCO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 26 th Annual Global Investment Conference being [...]

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

03/09/2024 - 22:01

SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]

Galapagos receives transparency notification from FMR LLC

03/09/2024 - 22:01

Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation 1 , [...]

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

03/09/2024 - 22:01

WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will [...]

Nkarta to Participate in Upcoming Investor Conference

03/09/2024 - 22:01

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the [...]

HealthEquity Reports Second Quarter Ended July 31, 2024 Financial Results

03/09/2024 - 22:01

Announces $300 Million Stock Repurchase Program Highlights of the second quarter include: Revenue of $299.9 million, an increase of 23% compared to $243.5 million in Q2 FY24. Net income of $35.8 million, compared to $10 [...]

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

03/09/2024 - 22:01

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s disease or who are [...]